Abstract:Background and objective Prostate-specific antigen (PSA) remains a critical marker for prostate cancer (PCa) detection and monitoring. Recognising historical variability in PSA assays and the evolution of assay technology and calibration, this study aims to reassess interassay variability using the latest generation of five assays in a contemporary cohort of men undergoing prostate biopsy. Methods Five different commercially available PSA assays were tested in a blood sample of 76 men before undergoing a prostate biopsy. Total PSA (tPSA) and free-to-total PSA ratio (%fPSA) were compared across assays, using Roche (Basel, Switzerland) as the benchmark, and correlated with biopsy outcome to analyse the impact on PCa diagnosis. The statistical analysis included Passing-Bablok regression and Bland-Altman plots, with a p value threshold of <0.05 for significance. Key findings and limitations Among the 76 men, 28 (36.8%) were diagnosed with significant PCa (defined as International Society of Urological Pathology grade ≥2). A high correlation was observed between tPSA and %fPSA values among the different PSA assays tested ( r 2 ≥ 0.9). The Passing-Bablok analysis showed that tPSA results varied substantially among the assays, with slopes ranging between 0.78 and 1.04. Compared with the tPSA of Roche, tPSA values were on average 20.7% lower by Beckman (Oststeinbeck, Germany), 15.2% lower by Abbott (Chicago, IL, USA), 6.1% lower by Diasorin (Saluggia, Italy), and 9.6% higher by Brahms (Hennigsdorf, Germany; p < 0.001 for all). The %fPSA values by Abbott and Brahms were higher at 15.7% and 10.6%, respectively ( p < 0.001), while the Beckman and Diasorin values had minimal differences of -0.3% and 2.3%, respectively ( p > 0.05). The variability across assays would have resulted in discrepancies in both the sensitivity and the specificity for tPSA and %fPSA by at least 14%, depending on the cut-offs applied. Conclusions and clinical implications Despite the use of the latest PSA assays, relevant variability of tPSA and %fPSA results can be observed among different assays. There is an urgent need for standardised calibration methods and greater awareness among practitioners concerning interassay variability. Clinicians should acknowledge that clinically relevant thresholds may depend on the specific PSA assay and that ideally the same assay is applied over time for better clinical decision-making. Patient summary Prostate-specific antigen (PSA) is a critical marker for prostate cancer (PCa) detection and monitoring. However, significant variations were observed in the results of the latest PSA assays. Thus, standardised calibration methods and greater awareness among practitioners concerning interassay variability are needed.

Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays

Percent Free Prostate-Specific Antigen for Prostate Cancer Diagnosis in Chinese Men with a PSA of 4.0–10.0 Ng/ml: Results from the Chinese Prostate Cancer Consortium

Does PSA level affect the choice of prostate puncture methods among MRI-ultrasound fusion targeted biopsy, transrectal ultrasound systematic biopsy or the combination of both?

The efficacy of different biomarkers and endpoints to refine referrals for suspected prostate cancer: the TARGET study (Tiered integrAted tests for eaRly diaGnosis of clinically significant ProstatE Tumours)

Diagnostic performance of total PSA an its derivatives for clinically significant prostate cancer and high-grade prostate cancer

Clinical Biofluid Assays for Prostate Cancer

Preanalytical stability of molecular forms of prostate‐specific antigen in serum samples (PSA, free PSA, [−2]proPSA) and their impact on fPSA/tPSA ratio and PHI

Unexpectedly high variability in determining tumour extent in prostatic biopsies: implications for active surveillance

[Clinical Value of Serum Isoform [-2] Proprostate-Specific Antigen and Its Derivatives in Predicting Aggressive Prostate Cancer].

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study

Performance of Serum Prostate-Specific Antigen Isoform [-2]Propsa (p2psa) and the Prostate Health Index (PHI) in a Chinese Hospital-Based Biopsy Population

Prostate-specific Antigen Density Variation Rate As a Potential Guideline Parameter for Second Prostate Cancer Detection Biopsy

B-347 Analytical Performance Evaluation of the High Sensitivity PSA Assay and the Free PSAII Assay on the Atellica IM Analyzer

64 A Snapshot of Prostate-Specific Antigen Testing in General Practices Across Three Primary Health Networks in Victoria

Clinical Performance of Serum Proprostate-Specific Antigen Isoform[-2] Propsa in Prostate Cancer

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1

Targeted Mass Spectrometry Assays for Specific Quantification of Urinary proPSA Isoforms

From Pro-Prostate Specific Antigen, [-2]Pro-prostate Specific Antigen to Beckman Coulter Phi: the Evolution of New Biomarkers for Early Detection of Prostatic Carcinoma.

[The Clinical Decision-Making Value of Prostate Specific Antigen and Its Derived Indicators in Prostate Imaging Reporting and Data System Version 2 3 Lesions].

A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into “Low-” and “High-Risk” Categories for Prostate Cancer

B-346 Diagnostic Performance of the Atellica IM Free PSA Assay in Men Undergoing Prostate Cancer Screening